{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:36:18Z","timestamp":1791401778826,"version":"4.3.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01657-z","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:27:51Z","timestamp":1737026871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1\/2 trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brent","family":"Ferrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"de Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Olutasidenib Combination Therapy Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1657_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"6","key":"1657_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute Myeloid Leukemia, Version 3. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721\u201349.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1657_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/leu.2016.275","volume":"31","author":"BC Medeiros","year":"2017","unstructured":"Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272\u201381.","journal-title":"Leukemia"},{"issue":"1","key":"1657_CR4","doi-asserted-by":"publisher","first-page":"12758","DOI":"10.1038\/s41598-017-12630-x","volume":"7","author":"DJ Urban","year":"2017","unstructured":"Urban DJ, Martinez NJ, Davis MI, Brimacombe KR, Cheff DM, Lee TD, et al. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. Sci Rep. 2017;7(1):12758.","journal-title":"Sci Rep"},{"issue":"4","key":"1657_CR5","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","volume":"63","author":"JA Caravella","year":"2020","unstructured":"Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, et al. Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020;63(4):1612\u201323.","journal-title":"J Med Chem"},{"issue":"11","key":"1657_CR6","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/cdd.2015.38","volume":"22","author":"M Itsumi","year":"2015","unstructured":"Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF, et al. Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)\/NADPH ratio. Cell Death Differ. 2015;22(11):1837\u201345.","journal-title":"Cell Death Differ"},{"issue":"2","key":"1657_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1073\/pnas.1618605114","volume":"114","author":"J Ye","year":"2017","unstructured":"Ye J, Gu Y, Zhang F, Zhao Y, Yuan Y, Hao Z, et al. IDH1 deficiency attenuates gluconeogenesis in mouse liver by impairing amino acid utilization. Proc Natl Acad Sci USA. 2017;114(2):292\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1657_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","volume":"3","author":"RA Cairns","year":"2013","unstructured":"Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3(7):730\u201341.","journal-title":"Cancer Discov"},{"issue":"7","key":"1657_CR9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood.2020007075","volume":"137","author":"Y Gu","year":"2021","unstructured":"Gu Y, Yang R, Yang Y, Zhao Y, Wakeham A, Li WY, et al. IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis. Blood. 2021;137(7):945\u201358.","journal-title":"Blood"},{"issue":"1","key":"1657_CR10","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","volume":"13","author":"R Reinbold","year":"2022","unstructured":"Reinbold R, Hvinden IC, Rabe P, Herold RA, Finch A, Wood J, et al. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Commun. 2022;13(1):4785.","journal-title":"Nat Commun"},{"key":"1657_CR11","doi-asserted-by":"crossref","unstructured":"Watts JM, Shaw SJ, Jonas BA. Looking beyond the surface: olutasidenib and ivosidenib for treatment of mIDH1 acute myeloid leukemia. Curr Treat Options Oncol. 2024;25(11):1345\u201353.","DOI":"10.1007\/s11864-024-01264-7"},{"issue":"1","key":"1657_CR12","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","volume":"10","author":"JM Watts","year":"2023","unstructured":"Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial. Lancet Haematol. 2023;10(1):e46\u201358.","journal-title":"Lancet Haematol"},{"key":"1657_CR13","doi-asserted-by":"crossref","unstructured":"de Botton S, Fenaux P, Yee KWL, Recher C, Wei AH, Montesinos P, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117\u201327.","DOI":"10.1182\/bloodadvances.2022009411"},{"issue":"24","key":"1657_CR14","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid Leukemia. J Clin Oncol. 2003;21(24):4642\u20139.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1657_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-Mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"1657_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","volume":"61","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, DiNardo CD, Konopleva M. Venetoclax in acute myeloid leukemia-current and future directions. Leuk Lymphoma. 2020;61(6):1313\u201322.","journal-title":"Leuk Lymphoma"},{"key":"1657_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107306","volume":"130","author":"J Edmund","year":"2023","unstructured":"Edmund J, Thaliath LJ, Meleveedu K. Acute myeloid leukemia in the medically unfit elderly patients. Leuk Res. 2023;130: 107306.","journal-title":"Leuk Res"},{"issue":"5","key":"1657_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022;12(5):77.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1657_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Dohner H, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324.","journal-title":"Am J Hematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01657-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01657-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01657-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:27:53Z","timestamp":1737026873000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01657-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01657-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and in compliance with good clinical practice guidelines and applicable laws. The protocol was approved by the institutional review boards or ethics committee at study sites. Written informed consent was obtained before study entry from each patient or from the patient\u2019s legally authorized representative if the patient was unable to provide consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JEC has received research funding for his current or former institution from, and is a consultant to, Astellas, Amphivena, BMS, Novartis, Pfizer, Takeda, Daiichi, Jazz Pharmaceuticals, Merus, and Forma Therapeutics; and is a consultant to Rigel, BiolineRx, Biopath, Sun Pharma, and Tern. GJR has served as a consultant for Agios, Amgen, Amphivena, Astex, Celator, Celgene, Clovis Oncology, CTI BioPharma, Genoptix, Immune Pharmaceuticals, Janssen Pharmaceuticals, Juno, MedImmune, MEI Pharma, Onconova, Pfizer, Roche, and Sunesis; received research funding from AbbVie, BMS, Teva and Karyopharm; is an advisory board member or consultant for Novartis, AbbVie, BeiGene, BerGenBio, Arcellx, Jazz Pharmaceuticals, Syros, BMS, Genentech, ImmunoGen, AstraZeneca, Kura, Ryvu, Magenta, and Qihan Zentalis; has provided research support to Janssen. MRB received research funding from Abbvie, Ascnetage Pharma, Forma Therapeutics, Kite\/Gilead, Kura Oncology, and Takeda. BAJ served in a consultancy\/advisory role for AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Kymera, Kura, Rigel, Schrodinger, Servier, Syndax and Treadwell, on a protocol steering committee for GlycoMimetics, on a data monitoring committee for Gilead, received travel reimbursement from AbbVie and Rigel, research funding to institution from AbbVie, Amgen, Aptose, AROG, Biomea, Bristol Myers Squibb, Celgene, Daiichi Sankyo, F. Hoffmann\u2011La Roche, Forma, Forty\u2011Seven, Genentech\/Roche, Gilead, GlycoMimetics, Hanmi, Immune\u2011Onc, Incyte, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. GJS has received advisory board and\/or speaker program honoraria from Agios, Stemline, GSK, AVM Biotech, Orca, Novartis, BMS, Rigel, Incyte, Gilead, Gamida, Autolus, Abbvie, Seattle Genetics, Jazz Pharmaceuticals, Kite (Gilead), Karyopharm, BMS\/Celgene, Blueprint Medicine, Astellas, and Amgen; has received consultant fees from BMS, Curios, Daichi-Sankyo, and Novartis; and holds stock or stock options in Amgen, Janssen, and BMS. KY was a consultant for Bristol Myers Squibb\/Celgene, F. Hoffmann-La Roche, GSK, Jazz Pharmaceuticals, Novartis, Pfizer, Shattuck Labs, Taiho Oncology, and Takeda; received research funding from Astex Pharmaceuticals, Forma Therapeutics, F. Hoffmann-La Roche, Forma Therapeutics, Genentech, Geron Corporation, Gilead Sciences, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novartis, and Treadwell Therapeutics; and received honoraria from AbbVie, TaiHo, and Novartis. PBF received unrelated research funding from Novartis. JY received research funding from Pfizer, Puretech, and Janssen. ESW served as advisory\/consulting for Abbvie, Blueprint, Daiichi Sankyo, Immunogen, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax, Takeda; speaking roles for Pfizer, Astellas, Dava (all with my own slides); served on DSMC for Gilead and Abbvie; and is section editor for UpToDate. WGB has no competing interests to declare. AM served on DSMC for Foghorn Therapeutics, Daiichi Saynko, advisory for BMS, Abbvie, Novartis, treadwell therapeutics, and is senior medical director for beat aml study for the leukemia and lymphoma society. HT and AS are employees and shareholders of Rigel Pharmaceuticals, Inc. SDB has received honoraria from AbbVie, Astellas Pharma, Bristol Myers Squibb, Jazz Pharmaceuticals, and Servier; has acted as a consultant or advisor to Bristol Myers Squibb, GlaxoSmithKline, Servier, and Syndax; has participated in speakers' bureau for AbbVie, Astellas Pharma, Bristol Myers Squibb, Jazz Pharmaceuticals, and Servier; has received research funding to his institution from Auron Therapeutics and Forma Therapeutics; and has received travel, accommodations, or expenses from AbbVie and Servier. PM has served as a consultant and has received research funding from Servier and Bristol Myers Squibb. AC received support for research\/honoraria for advisory boards and meetings from Abbvie and Pfizer; received honoraria for advisory board and meetings from Menarini Stemline, Jazz Pharmaceutical and Servier. JMW has received research funding from and was a board\/advisory committee member for Takeda; has received research funding from Immune System Key Ltd; and is a consultant or board\/advisory committee member for Genentech, Rafael Pharma, Reven Pharma, Celgene\/Bristol-Myers Squib (BMS), Servier, Rigel, Aptose, Astellas, and Daiichi-Sankyo. BAJ served in a consultancy\/advisory role for AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Kymera, Kura, Rigel, Schrodinger, Servier, Syndax and Treadwell, on a protocol steering committee for GlycoMimetics, on a data monitoring committee for Gilead, received travel reimbursement from AbbVie and Rigel, research funding to institution from AbbVie, Amgen, Aptose, AROG, Biomea, Bristol Myers Squibb, Celgene, Daiichi Sankyo, F. Hoffmann\u2011La Roche, Forma, Forty\u2011Seven, Genentech\/Roche, Gilead, GlycoMimetics, Hanmi, Immune\u2011Onc, Incyte, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. GJS has received advisory board and\/or speaker program honoraria from Agios, Stemline, GSK, AVM Biotech, Orca, Novartis, BMS, Rigel, Incyte, Gilead, Gamida, Autolus, Abbvie, Seattle Genetics, Jazz Pharmaceuticals, Kite (Gilead), Karyopharm, BMS\/Celgene, Blueprint Medicine, Astellas, and Amgen; has received consultant fees from BMS, Curios, Daichi-Sankyo, and Novartis; and holds stock or stock options in Amgen, Janssen, and BMS. KY was a consultant for Bristol Myers Squibb\/Celgene, F. Hoffmann-La Roche, GSK, Jazz Pharmaceuticals, Novartis, Pfizer, Shattuck Labs, Taiho Oncology, and Takeda; received research funding from Astex Pharmaceuticals, Forma Therapeutics, F. Hoffmann-La Roche, Forma Therapeutics, Genentech, Geron Corporation, Gilead Sciences, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novartis, and Treadwell Therapeutics; and received honoraria from AbbVie, TaiHo, and Novartis. PBF received unrelated research funding from Novartis. JY received research funding from Pfizer, Puretech, and Janssen. ESW served as advisory\/consulting for Abbvie, Blueprint, Daiichi Sankyo, Immunogen, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax, Takeda; speaking roles for Pfizer, Astellas, Dava (all with my own slides); served on DSMC for Gilead and Abbvie; and is section editor for UpToDate. WGB has no competing interests to declare. AM served on DSMC for Foghorn Therapeutics, Daiichi Saynko, advisory for BMS, Abbvie, Novartis, treadwell therapeutics, and is senior medical director for Beat AML study for the Leukemia and Lymphoma Society. HT and AS are employees and shareholders of Rigel Pharmaceuticals, Inc. SDB has received honoraria from AbbVie, Astellas Pharma, Bristol Myers Squibb, Jazz Pharmaceuticals, and Servier; has acted as a consultant or advisor to Bristol Myers Squibb, GlaxoSmithKline, Servier, and Syndax; has participated in speakers' bureau for AbbVie, Astellas Pharma, Bristol Myers Squibb, Jazz Pharmaceuticals, and Servier; has received research funding to his institution from Auron Therapeutics and Forma Therapeutics; and has received travel, accommodations, or expenses from AbbVie and Servier. PM has served as a consultant and has received research funding from Servier and Bristol Myers Squibb. AC received support for research\/honoraria for advisory boards and meetings from Abbvie and Pfizer; received honoraria for advisory board and meetings from Menarini Stemline, Jazz Pharmaceutical and Servier. JMW has received research funding from and was a board\/advisory committee member for Takeda; has received research funding from Immune System Key Ltd; and is a consultant or board\/advisory committee member for Genentech, Rafael Pharma, Reven Pharma, Celgene\/Bristol-Myers Squib (BMS), Servier, Rigel, Aptose, Astellas, and Daiichi-Sankyo.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}